These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29683434)

  • 21. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
    Subbaraman H; Schanz M; Trkola A
    Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System.
    Bhiman JN; Lynch RM
    Curr HIV/AIDS Rep; 2017 Apr; 14(2):54-62. PubMed ID: 28349376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
    Trkola A; Kuster H; Rusert P; Joos B; Fischer M; Leemann C; Manrique A; Huber M; Rehr M; Oxenius A; Weber R; Stiegler G; Vcelar B; Katinger H; Aceto L; Günthard HF
    Nat Med; 2005 Jun; 11(6):615-22. PubMed ID: 15880120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention.
    Brady JM; Baltimore D; Balazs AB
    Immunol Rev; 2017 Jan; 275(1):324-333. PubMed ID: 28133808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineering strategies of Anti-HIV antibody therapeutics in clinical development.
    Pihlstrom N; Bournazos S
    Curr Opin HIV AIDS; 2023 Jul; 18(4):184-190. PubMed ID: 37144557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.
    Sanchez-Merino V; Fabra-Garcia A; Gonzalez N; Nicolas D; Merino-Mansilla A; Manzardo C; Ambrosioni J; Schultz A; Meyerhans A; Mascola JR; Gatell JM; Alcami J; Miro JM; Yuste E
    J Virol; 2016 Jun; 90(11):5231-5245. PubMed ID: 26984721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.
    González N; McKee K; Lynch RM; Georgiev IS; Jimenez L; Grau E; Yuste E; Kwong PD; Mascola JR; Alcamí J
    PLoS One; 2018; 13(3):e0193773. PubMed ID: 29558468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of broadly neutralizing antibodies for HIV-1 prevention.
    Pegu A; Hessell AJ; Mascola JR; Haigwood NL
    Immunol Rev; 2017 Jan; 275(1):296-312. PubMed ID: 28133803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype.
    Cornelissen M; Euler Z; van den Kerkhof TL; van Gils MJ; Boeser-Nunnink BD; Kootstra NA; Zorgdrager F; Schuitemaker H; Prins JM; Sanders RW; van der Kuyl AC
    AIDS Res Hum Retroviruses; 2016; 32(10-11):1135-1142. PubMed ID: 26910384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies.
    Parsons MS; Chung AW; Kent SJ
    Retrovirology; 2018 Aug; 15(1):58. PubMed ID: 30134945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.
    Lu CL; Murakowski DK; Bournazos S; Schoofs T; Sarkar D; Halper-Stromberg A; Horwitz JA; Nogueira L; Golijanin J; Gazumyan A; Ravetch JV; Caskey M; Chakraborty AK; Nussenzweig MC
    Science; 2016 May; 352(6288):1001-4. PubMed ID: 27199430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virological features associated with the development of broadly neutralizing antibodies to HIV-1.
    Moore PL; Williamson C; Morris L
    Trends Microbiol; 2015 Apr; 23(4):204-11. PubMed ID: 25572881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.
    Freund NT; Wang H; Scharf L; Nogueira L; Horwitz JA; Bar-On Y; Golijanin J; Sievers SA; Sok D; Cai H; Cesar Lorenzi JC; Halper-Stromberg A; Toth I; Piechocka-Trocha A; Gristick HB; van Gils MJ; Sanders RW; Wang LX; Seaman MS; Burton DR; Gazumyan A; Walker BD; West AP; Bjorkman PJ; Nussenzweig MC
    Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.
    Boesch AW; Alter G; Ackerman ME
    Curr Opin HIV AIDS; 2015 May; 10(3):160-9. PubMed ID: 25700208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.
    Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE
    J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV Broadly Neutralizing Antibodies: Taking Good Care Of The 98.
    Sok D; Burton DR
    Immunity; 2016 Nov; 45(5):958-960. PubMed ID: 27851923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.